Abstract

Introduction

Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non–clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients.

In nccRCC patients, treatment with pazopanib was effective and feasible; dose reductions required for toxicity were similar as expected in ccRCC.

Micro-Abstract

In this retrospective study we focused on a subgroup of rare tumors, such as non–clear-cell renal cancers, with the aim to provide evidence of activity and feasibility of a multityrosine kinase inhibitor, pazopanib, as a first-line treatment alternative to the widely used sunitinib. Our conclusions support the use of pazopanib in this subgroup, awaiting prospective results of ongoing clinical trials.